We have all heard the warnings that the rate of avoidable medical errors is staggeringly high, with estimations of hundreds of thousands of preventable deaths annually in the US. Deaths from medical error has even been referred to by some as an epidemic. These reports have become viral in their reach by infiltrating the lay […]

Small cell lung cancer (SCLC) is a devastating diagnosis, and new therapeutic options are desperately needed in this setting. Previously, first-line treatment of extensive-stage SCLC was limited to combination chemotherapy, which is associated with modest overall survival (OS), but inroads have been made with the application of immune checkpoint inhibitor antibodies to this setting. Immunotherapy […]

On June 18, 2019, the United States Food and Drug Administration granted accelerated approval to the PD-1 inhibitor pembrolizumab for use as a monotherapy in the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other line of therapy. This approval was […]

Chimeric antigen receptor (CAR)-modified T cells have become an important treatment option for some patients with hematologic malignancies, including non-Hodgkin lymphoma and acute leukemias. However, CAR T-cell treatment can be associated with cytokine release syndrome (CRS), which limits its utility by restricting administration only to experienced centers capable of managing this potentially fatal event. In […]